Spotlight/ Insights Reviewing Component Mechanisms of Peripheral CB1 Inhibitor Antibody Date published: September 4, 2025 3:00 pm PDT Share Copied! Skye’s CMO and CSO discuss key differentiating mechanistic components of our peripherally-restricted CB1-inhibiting antibody, nimacimab. Related Documents: Anatomy of Progress-Four Pillars: Slides